DigiStain – the UK’s First Breast Cancer Risk Profiling Technology

Why Digistain?

0 %
Reduction in patient waiting times
0 %
Equivalent to the best in class risk profiling tests used today
0 %
Overall cost reduction through avoided chemotherapy
0 %
Multi-site reproducibility with routinely trained lab technicians

Digistain for patients is a patented risk profiling test for hormone receptor-positive breast cancer patients approved by the UK’s Medicines & Healthcare products Regulatory Agency. It reports thelikelihood of breast cancer recurrence when treated with hormone therapy alone.

Digistain is designed for patients who have been diagnosed with invasive breast cancer who are Stage 1 or 2, HER2-, ER+ or < 3 malignant lymph nodes. It provides a 10 Year Risk of Recurrence Breast Cancer Risk Report with detailed information on your result, for the best course action and treatment. 

Digistain’s has undergone several clinical trials demonstrating a prognostic score with risk classification equivalent to the best in class genomic tests
The product of 15 years of R&D pioneered by respected cancer researchers from Imperial College London and Cancer Research UK
Digistain's Prognostic Score uses a proprietary optical scan of the tumour tocapture a spectral signature (of over 10,000 data points) that is unique to every patient.

Risk Actionable Information in Under 1 Hour

Digistain Prognostic Score

Unlike first-generation genomic tests used in hospitals around the world today, Digistain works biologically downstream to measure markers at the protein level. It, therefore, avoids the quality control and reproducibility issues common to RNA isolation from formalin-fixed tissue. 

The advantage of working downstream is that Digistain’s unique approach is much closer to the patient-outcome than biologically upstream laboratory protocols and is robust to clinical protocol variabilities.

In a recent landmark trial of over 840 patients, Digistain’s Prognostic Score demonstrated unequivocal equivalence to the best-in-class genomics tests in use today.


For Patients

Supported by:

Subscribe to leading news and insights

To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.